Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19

The interleukin-6 inhibitor will be evaluated in critically ill patients

- PMLiVE

Lilly and AbCellera partner on antibody therapies for COVID-19

Latest companies to join the fight against the novel coronavirus

- PMLiVE

Lilly joins new Medicare scheme to reduce insulin prices

New model will cover seniors enrolled in Medicare Part D

- PMLiVE

FDA clears wider use for Boehringer’s Ofev in lung disease

Drug was first approved in 2014 for pulmonary fibrosis

Sanofi reception

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

First cancer drug wholly owned by company to be approved in past decade

- PMLiVE

Modest meeting sees only two drugs recommended by CHMP

Lilly’s migraine med Emgality receives negative opinion for label extension

- PMLiVE

Boehringer links up with Trutino for cancer R&D

Collaboration agreement will focus on cytokine treatments

- PMLiVE

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Advisory committee voted 6-5 in favour of drug

Sanofi reception

Sanofi says it will spin out active ingredient business by 2022

New chief exec Paul Hudson continues revamp

- PMLiVE

As new coronavirus outbreaks emerge, fears of a global pandemic escalate

Increased quarantine measures are reported across the globe

- PMLiVE

Lilly’s Trulicity scores CV reduction indication in the US

Approved for risk reduction in primary and secondary populations

- PMLiVE

US backs Sanofi’s ‘fast-track’ coronavirus vaccine

Development will tap into earlier work on the SARS virus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links